Chimeric Therapeutics Limited Receivables

Chimeric Therapeutics Limited posts a receivables of $29K as of June 2026. That compares with $4.6M in the prior-year period — down 99.4% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Chimeric Therapeutics Limited's receivables was $4.6M. The latest reading is $29K — a 99.4% year-over-year decrease (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Receivables is one piece of Chimeric Therapeutics Limited's financial statement story. At $29K, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CHMMF's receivables usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Chimeric Therapeutics Limited's other metric pages and overview cover the third.

Judging Chimeric Therapeutics Limited against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in receivables easier to interpret. Start with $29K here, then scan peer and history charts to see if the gap is persistent.